MN-221: Final Phase II data

Final data from 29 patients in a single-blind, U.S. Phase II trial (MN-221-CL-006) showed that the hospitalization rate was 25% in patients receiving MN-221 plus SOC vs. 46% for SOC alone. SOC consist...